



## BioLineRx to Present at 2016 BIO CEO & Investor Conference in New York on February 8

February 1, 2016

TEL AVIV, Israel, February 1, 2016 /PRNewswire/ --

BioLineRx (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer, Kinneret Savitsky, Ph.D., and its Chief Financial and Operating Officer, Philip Serlin, will present a company update at the 2016 BIO CEO & Investor Conference on Monday, February 8, 2016 at 2:30 pm EST. The conference will be held at the Waldorf Astoria Hotel in New York.

A live webcast of the presentation will be available on BioLineRx's [website](#). A replay will be available one hour after the presentation ends and will be accessible for three months following the presentation.

Investors or potential partners attending the conference who wish to meet with Dr. Savitsky or Mr. Serlin should contact the BIO Partnering Team at [biopartnering@bio.org](mailto:biopartnering@bio.org).

### About BioLineRx

BioLineRx is a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates. The Company in-licenses novel compounds primarily from academic institutions and biotech companies based in Israel, develops them through pre-clinical and/or clinical stages, and then partners with pharmaceutical companies for advanced clinical development and/or commercialization.

BioLineRx's leading therapeutic candidates are: BL-8040, a cancer therapy platform, which is in the midst of a Phase 2 study for relapsed/refractory AML, has recently initiated a Phase 2b study as an AML consolidation treatment, has recently initiated a Phase 1/2 study in hMDS and AA, and has successfully completed a Phase 1 study in stem cell mobilization; and BL-7010 for celiac disease, which has successfully completed a Phase 1/2 study. In addition, BioLineRx has a strategic collaboration with Novartis for the co-development of selected Israeli-sourced novel drug candidates, and has recently announced an immuno-oncology collaboration with Merck for the combination of BL-8040 and Keytruda in pancreatic cancer.

For more information on BioLineRx, please visit <http://www.bioprx.com> or download the investor relations mobile device app, which allows users access to the Company's SEC documents, press releases, and events. BioLineRx's IR app is available on the iTunes App Store as well as the Google Play Store.

### Contacts for BioLineRx:

PCG Advisory  
Vivian Cervantes  
Investor Relations  
+1-212-554-5482  
[vivian@pcgadvisory.com](mailto:vivian@pcgadvisory.com)

or

Tsipi Haitovsky  
Public Relations  
+972-3-624-0871  
[tsipihai5@gmail.com](mailto:tsipihai5@gmail.com)

SOURCE BioLineRx Ltd